Share on LinkedInShare on LinkedIn

ARTICLE · 03 JULY 2012

PMPRB Reconsiders And Issues New Decision On Quadracel® And Pentacel®

Gowling WLG
Gowling WLG
Contributor
Gowling WLG

Gowling WLG

The firm The firm’s lawyers speak English, French, Russian and Ukrainian. The firm’s client base...

View firm profile
Explore more from Gowling WLG

The PMPRB released its June 14, 2012 decision relating to Sanofi Pasteur’s vaccines QUADRACEL and PENTACEL.

CanadaIntellectual Property

The PMPRB released its June 14, 2012 decision relating to Sanofi Pasteur's vaccines QUADRACEL and PENTACEL.   Following reconsideration, it opted to issue an order for the identical amounts as were found to be owing under its previous order that the Federal Court of Canada had declared a nullity.

This is the next chapter following the Federal Court's July 12, 2011 decision (Sanofi Pasteur Limited v. Attorney General of Canada 2011 FC 859 (T-83-10)) ("Sanofi") (http://decisions.fct-cf.gc.ca/en/2011/2011fc859/2011fc859.html) that declared a decision of the Patented Medicine Prices Review Board ("Board") to be null and void.  It  required the Board to return amounts paid by Sanofi Pasteur pursuant to the Board's order, and directed the matter back for reconsideration.  

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from